Claims

1. Use of an inhibitor of the interaction between the PD-1 receptor and its ligand PD-L1, wherein the inhibitor is an anti-PD-L1 antibody comprising in its heavy chain the three complementarity determining regions (CDR's) according to SEQ ID NO's: 1, 2 and 3, and in its light chain the three complementarity determining regions (CDRs) according to SEQ ID NOs: 4, 5 and 6, in the manufacture of a medicament for the treatment of urothelial carcinoma in a subject.

2. The use according to Claim 1, wherein the subject is human, the PD-1 receptor is human PD-1 receptor, and PD-L1 is human PD-L1.

3. The use according to any one of Claims 1-2, wherein the cancer is identified as a PD-L1 positive cancer.

4. The use according to any of the preceding Claims, wherein the anti-PD-L1 antibody is Avelumab, having the heavy chain sequences according to SEQ ID NOs: 7 or 8 and the light chain sequence according to SEQ ID NO:9.

5. The use according to any of Claims 1-4 wherein the anti-PD-L1 antibody is to be administered at a dose of 10 mg/kg body weight every other week.

6. The use according to any of Claims 1-5, wherein the anti-PD-L1 antibody is to be administered as an intravenous infusion.

7. The use according to Claim 6, wherein the anti-PD-L1 antibody is to be administered as a one-hour intravenous infusion.

8. The use according to any one of Claims 1 -7, wherein the medicament results in an objective response, preferably a complete response or a partial response.

9.The use according to any one of Claims 1-8, wherein the subject has previously received chemotherapy.

10. The use according to Claim 9, wherein the chemotherapy comprises a platinum containing chemotherapeutic agent.

11. The use according to any of Claims 1-10, wherein the urothelial carcinoma is locally advanced or metastatic.